We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-5.44%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.92B
AUM Growth
-$82.3M
Cap. Flow
-$215M
Cap. Flow %
-11.22%
Top 10 Hldgs %
52.67%
Holding
387
New
94
Increased
95
Reduced
80
Closed
99

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$12.5M
2
ABT icon
Abbott
ABT
+$10.5M
3
OTLK icon
Outlook Therapeutics
OTLK
+$7.71M
4
BPTH
Bio-Path Holdings Inc
BPTH
+$7.56M
5
SHPG
Shire pic
SHPG
+$5.34M

Top Sells

Rank Stock Value
1
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$22.6M
2
BIIB icon
Biogen
BIIB
+$7.14M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$3.88M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$3.22M
5
ESRX
Express Scripts Holding Company
ESRX
+$2.84M

Sector Composition

Rank Sector Weight
1 Healthcare 12.85%
2 Industrials 0.12%
3 Consumer Staples 0.07%
4 Consumer Discretionary 0.06%
5 Technology 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XTLB
151
XTL Biopharmaceuticals
XTLB
$6.64M
$1.16M 0.06%
50,059
-1,951
-4% -$41.9K
BCLI
152
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
$1.15M 0.06%
31,781
-1,098
-3% -$38.5K
CEMP
153
DELISTED
Cempra, Inc.
CEMP
$1.06M 0.06%
64,065
-35,935
-36% -$634K
NVAX icon
154
Novavax
NVAX
$1.21B
$1.04M 0.05%
+7,136
New +$818K
IMUC
155
DELISTED
ImmunoCellular Therapeutics, Ltd.
IMUC
$1.02M 0.05%
111,303
+1,019
+0.9% +$10.5K
KPRX icon
156
Kiora Pharmaceuticals
KPRX
$11.5M
$1M 0.05%
+72
New +$1.25M
ONCS
157
DELISTED
OncoSec Medical Incorporated
ONCS
$997K 0.05%
2,764
-2,288
-45% -$964K
IMMU
158
DELISTED
Immunomedics Inc
IMMU
$986K 0.05%
+425,000
New +$1.42M
TXMD icon
159
CALL
TherapeuticsMD
TXMD
$23.7M
$980K 0.05%
23
+13
+130% +$5.36K
GALT icon
160
Galectin Therapeutics
GALT
$234M
$974K 0.05%
662,467
-410,298
-38% -$602K
RIGL icon
161
Rigel Pharmaceuticals
RIGL
$704M
$972K 0.05%
+43,596
New +$1.08M
ACUR
162
DELISTED
Acura Pharmaceuticals
ACUR
$959K 0.05%
518,444
-130,440
-20% -$337K
ARMP icon
163
Armata Pharmaceuticals
ARMP
$177M
$951K 0.05%
+4,384
New +$1.51M
KTOVW
164
DELISTED
Kitov Pharma Ltd. Warrants
KTOVW
$944K 0.05%
1,210,785
+1,096,065
+955% +$1.62M
ENDP
165
DELISTED
Endo International plc
ENDP
$936K 0.05%
60,061
+10,061
+20% +$208K
GNVC
166
DELISTED
GenVec, Inc.
GNVC
$931K 0.05%
+162,544
New +$1.14M
JUNO
167
CALL
DELISTED
Juno Therapeutics, Inc.
JUNO
$923K 0.05%
240
+173
+258% +$7.18K
DXTR
168
DELISTED
Dextera Surgical Inc.
DXTR
$868K 0.05%
+482,000
New +$987K
CSCI
169
DELISTED
COSCIENS Biopharma Inc. Common Stock
CSCI
$867K 0.05%
2,658
-2,267
-46% -$816K
WINT
170
DELISTED
Windtree Therapeutics Inc
WINT
$866K 0.05%
448,509
-117,843
-21% -$285K
DERM
171
PUT
DELISTED
Dermira, Inc.
DERM
$845K 0.04%
289
+189
+189% +$5.21K
CLVS
172
DELISTED
Clovis Oncology, Inc.
CLVS
$821K 0.04%
59,836
+46,510
+349% +$680K
CASC
173
DELISTED
Cascadian Therapeutics, Inc.
CASC
$815K 0.04%
144,067
+20,900
+17% +$142K
VTVT icon
174
vTv Therapeutics
VTVT
$125M
$811K 0.04%
3,494
– –
OCRX
175
DELISTED
Ocera Therapeutics, Inc.
OCRX
$806K 0.04%
424,035
+25,000
+6% +$65.7K
5 6
7
8 9

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q2 2016 Portfolio in Review

As of Q2 2016, Sabby Management held 387 positions worth $1.92B, down 4.1% from $2B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Sabby Management withdrew a net $215M in Q2 2016, closing 99 positions and reducing 80 holdings. Its most notable exit was State Street SPDR S&P 500 ETF Trust, an estimated $22.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 13% of assets, up from 12% a quarter earlier, followed by Industrials and Consumer Staples.

Against the trend, Sabby Management opened a new position in Abbott worth $10.4M.

  • Sabby Management's largest Q2 2016 buy was Abbott: 264,700 shares worth $10.4M.
  • Sabby Management added most to Regeneron Pharmaceuticals in Q2 2016, an estimated $12.5M increase.
  • Sabby Management's biggest Q2 2016 reduction was Biogen, cutting an estimated $7.14M.
  • Sabby Management fully exited State Street SPDR S&P 500 ETF Trust in Q2 2016, selling an estimated $22.6M.
  • Sabby Management's ten largest holdings make up 53% of its $1.92B portfolio in Q2 2016.
  • Sabby Management opened 94 new positions and closed 99 in Q2 2016.
  • Sabby Management's portfolio value fell 4.1% quarter-over-quarter to $1.92B.

Based on Sabby Management's 13F filing for Q2 2016, filed 15 Aug 2016.